Biogen Decline Over PML Tied To Tecfidera, Offers Investors A Lower Entry Point
BMD Asset Management and Research • Tue, Oct. 28
- Biogen reported strong Q3 earnings. While the stock price has risen over 24% in the last year, the valuation still looks reasonable.
- Analysts have raised their earnings estimates 6.1% this year and 3.4% next year.
- Biogen is up more than 24% in the last year, but down 8% since the September high. The stock still has at least 22.3% upside remaining.